

## **PolyPid to Report Second Quarter 2022 Financial Results and Operational Highlights on August 10, 2022**

PETACH TIKVA, Israel, July 27, 2022 — PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its second quarter 2022 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, August 10, 2022. The Company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the results and provide an update on business operations.

To access the live call via telephone, please register in advance using the link **here**. Upon registering, each participant will receive an email confirmation with dial-in numbers and a unique personal PIN that can be used to join the call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call.

For those not planning to ask management a question, the Company recommends listening via the webcast using the link **here**.

### **Conference Call Dial-In & Webcast Information:**

Date: Wednesday, August 10, 2022

Time: 8:30 a.m. Eastern Time

Q&A participants: <https://register.vevent.com/register/BI985b31488d2141f99e4e9db5d66810fd>

Live Webcast: <https://edge.media-server.com/mmc/p/itwzz9g3>

### **About PolyPid**

PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX<sub>100</sub> is in Phase 3 clinical trials for the prevention of soft tissue abdominal and sternal bone surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for treatment of solid tumors, beginning with glioblastoma.

For additional Company information, please visit <http://www.polypid.com> and follow us on Twitter and LinkedIn.

References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is

not responsible for the contents of third-party websites.

**Contacts:**

PolyPid Ltd.

Ori Warshavsky

COO - US

908-858-5995

**Investors:**

Bob Yedid

LifeSci Advisors

646-597-6989

Bob@LifeSciAdvisors.com

**Media:**

Nechama Feuerstein

FINN Partners

551-444-0784

Nechama.Feuerstein@finnpartners.com

